By day 29 of the trial, 11.2% in the remdesivir group and 11.3% in the control group had an adverse cardiac event.
Study shows no link between remdesivir, cardiac events
Published in COVID-19
May 2, 2024
The International Organization for the Proctection Against COVID-19
By day 29 of the trial, 11.2% in the remdesivir group and 11.3% in the control group had an adverse cardiac event.
Published in COVID-19